Patents Represented by Attorney Kalim S. Fuzail
  • Patent number: 8119385
    Abstract: The invention provides polypeptides, including enzymes, structural proteins and binding proteins, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. Polypeptides, including enzymes and antibodies, and nucleic acids of the invention can be used in industrial, experimental, food and feed processing, nutritional and pharmaceutical applications, e.g., for food and feed supplements, colorants, neutraceuticals, cosmetic and pharmaceutical needs.
    Type: Grant
    Filed: March 3, 2006
    Date of Patent: February 21, 2012
    Assignee: BP Corporation North America Inc.
    Inventors: Eric J. Mathur, Cathy Chang
  • Patent number: 8101393
    Abstract: The invention provides polypeptides having any cellulolytic activity, e.g., a cellulase activity, a endoglucanase, a cellobiohydrolase, a beta-glucosidase, a xylanase, a mannanse, a ?-xylosidase, an arabinofuranosidase, and/or an oligomerase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides having any cellulolytic activity, e.g., a cellulase activity, e.g., endoglucanase, cellobiohydrolase, beta-glucosidase, xylanase, mannanse, ?-xylosidase, arabinofuranosidase, and/or oligomerase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. In one aspect, the invention provides polypeptides having an oligomerase activity, e.g., enzymes that convert recalcitrant soluble oligomers to fermentable sugars in the saccharification of biomass.
    Type: Grant
    Filed: December 8, 2006
    Date of Patent: January 24, 2012
    Assignee: BP Corporation North America Inc.
    Inventors: Kevin A. Gray, Lishan Zhao, Michelle H. Cayouette
  • Patent number: 8043839
    Abstract: The invention relates to enzymes having xylanase, mannanase and/or glucanase activity, e.g., catalyzing hydrolysis of internal ?-1,4-xylosidic linkages or endo-?-1,4-ghicanase linkages; and/or degrading a linear polysaccharide beta-1,4-xylan into xylose. Thus, the invention provides methods and processes for breaking down hemicellulose, which is a major component of the cell wall of plants, including methods and processes for hydrolyzing hemicelluloses in any plant or wood or wood product, wood waste, paper pulp, paper product or paper waste or byproduct. In addition, methods of designing new xylanases, mannanases and/or glucanases and methods of use thereof are also provided. The xylanases, mannanases and/or glucanases have increased activity and stability at increased pH and temperature.
    Type: Grant
    Filed: February 14, 2007
    Date of Patent: October 25, 2011
    Assignee: Verenium Corporation
    Inventors: David Weiner, David Blum, Alexander Varvak, Shaun Healey, Kristine Chang, Geoff Hazlewood, Thomas Todaro, Grace Desantis, Hwai Chang, Connie Jo Hansen, Scott W. Beaver, Thomas Woodward, Charles Hancock
  • Patent number: 7960148
    Abstract: The invention relates to polypeptides having glucanase, e.g., endoglucanase, mannanase, xylanase activity or a combination of these activities, and polynucleotides encoding them. In one aspect, the glucanase activity is an endoglucanase activity (e.g., endo-1,4-beta-D-glucan 4-glucano hydrolase activity) and comprises hydrolysis of 1,4-beta-D-glycosidic linkages in cellulose, cellulose derivatives (e.g., carboxy methyl cellulose and hydroxy ethyl cellulose) lichenin, beta-1,4 bonds in mixed beta-1,3 glucans, such as cereal beta-D-glucans or xyloglucans and other plant material containing cellulosic parts. In addition, methods of designing new enzymes and methods of use thereof are also provided. In alternative aspects, the new glucanases e.g., endoglucanases, mannanases, xylanases have increased activity and stability at increased pH and temperature.
    Type: Grant
    Filed: July 2, 2004
    Date of Patent: June 14, 2011
    Assignees: Verenium Corporation, Syngenta Participations AG
    Inventors: Brian Steer, Walter Callen, Shaun Healey, Derrick Pulliam
  • Patent number: 6864369
    Abstract: New crystalline forms of lopinavir are disclosed.
    Type: Grant
    Filed: March 12, 2003
    Date of Patent: March 8, 2005
    Assignee: Abbott Laboratories
    Inventors: Daniel A. Dickman, Sanjay Chemburkar, James J. Fort, Rodger F. Henry, David Lechuga-Ballesteros, Yuping Niu, William Porter
  • Patent number: 6667404
    Abstract: A retroviral protease inhibiting compound of the formula: is disclosed.
    Type: Grant
    Filed: February 7, 2003
    Date of Patent: December 23, 2003
    Assignee: Abbott Laboratories
    Inventors: Dale J. Kempf, Daniel W. Norbeck, Hing Leung Sham, Chen Zhao, Thomas J. Sowin, Daniel S. Reno, Anthony R. Haight
  • Patent number: 6630476
    Abstract: Corticotropin releasing factor (CRF) antagonists of Formula (I) or (II) and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
    Type: Grant
    Filed: July 3, 2001
    Date of Patent: October 7, 2003
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventor: Rajagopal Bakthavatchalam
  • Patent number: 6613790
    Abstract: A compound of Formula (I), or a pharmaceutically-acceptable salt thereof, suitable for use in the treatment of a cyclooxygenase-2 mediated disease is provided. Also provided is a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically-acceptable salt thereof, and a method for treatment of a cyclooxygenase-2 mediated disease by administering to a subject in need thereof a therapeutically-effective amount of the pharmaceutical composition.
    Type: Grant
    Filed: April 16, 2002
    Date of Patent: September 2, 2003
    Assignee: Pharmacia Corporation
    Inventor: Jeffery S. Carter
  • Patent number: 6589521
    Abstract: A composition of (Z)-11-tetradecenyl acetate and (Z)-11-tetradecenal in a weight ratio of about 50:50 to about 90:10 is a highly effective mating disruptant for the male Orange Tortrix and Omniverous Leafroller moths. In a preferred embodiment, the weight ratio of (Z)-11-tetradecenyl acetate and (Z)-11-tetradecenal is about 75:25. The composition demonstrates biological activity in the form of enhanced mating disruption efficacy that is greater than any discovery or development to date for the Orange Tortrix of the Omniverous Leafroller.
    Type: Grant
    Filed: June 5, 2000
    Date of Patent: July 8, 2003
    Assignee: Scentry Biologicals, Inc.
    Inventor: Jeffrey White
  • Patent number: 6448261
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I; and their use in treating anxiety, depression, and other psychiatric and neurological disorders.
    Type: Grant
    Filed: March 14, 2000
    Date of Patent: September 10, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Rajagopal Bakthavatchalam, Argyrios Georgios Arvanitis, James Peter Beck, Gary Avonn Cain, Robert John Chorvat, Paul Joseph Gilligan, Richard Eric Olson
  • Patent number: 6365589
    Abstract: The present invention describes novel imidazo-pyridines, -pyridazines, and -triazines of formula I: wherein A and B can be C or N and D is aryl or heteroaryl or pharmaceutically acceptable salt forms thereof, which are useful as CRF antagonists.
    Type: Grant
    Filed: June 25, 1999
    Date of Patent: April 2, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Paul Joseph Gilligan, Richard Eric Olson, William Eric Frietze
  • Patent number: 6362180
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula (I): and their use in treating psychiatric disorders and neurological diseases, anxiety-related disorders, post-traumatic stress disorder, supranuclear palsy and feeding disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress in mammals.
    Type: Grant
    Filed: December 10, 1998
    Date of Patent: March 26, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Richard Gerald Wilde, Rajagopal Bakthavatchalam, James Peter Beck, Argyrios Georgious Arvanitis
  • Patent number: 6352990
    Abstract: CRF receptor antagonists are disclosed which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke.
    Type: Grant
    Filed: October 8, 1999
    Date of Patent: March 5, 2002
    Assignee: Bristol-Myers Squibb Company
    Inventor: James R. McCarthy
  • Patent number: 6346517
    Abstract: This invention is directed to a combination therapy comprising the administration of a low molecular weight heparin such as tinzaparin and a platelet GPIIb/IIIa antagonist such as roxifiban for treating, preventing and reducing the risk of thromboembolic disorders.
    Type: Grant
    Filed: March 10, 2000
    Date of Patent: February 12, 2002
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Pancras C. Wong, Shaker A. Mousa
  • Patent number: 6342503
    Abstract: The present invention provides novel compounds, compounds and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsy, irritable bowel syndrome, immune suppression, Alzheimer'disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems. The novel compounds provided by this invention are those of formula: wherein R1, R3, R4, R5, Z, Y, V, X, X′, J, K, L, and M are as defined herein.
    Type: Grant
    Filed: January 7, 1998
    Date of Patent: January 29, 2002
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Paul Edward Aldrich, Argyrios Georgios Arvanitis, Robert Scott Cheeseman, Robert John Chorvat, Thomas Eugene Christos, Paul Joseph Gilligan, Dimitri Emil Grigoriadis, Carl Nicholas Hodge, Paul John Krenitsky, Everett Latham Scholfield, Sang William Tam, Zelda Rakowitz Wasserman
  • Patent number: 6326162
    Abstract: This invention is directed to assays to determine the presence or absence of proteins that exhibit aggrecanase or ADMP activity. This invention also relates to peptides that acts as a substrates for ADMPs, their use in various assays to determine the presence or absence of ADMP activity, and their use as inhibitors of ADMP activity.
    Type: Grant
    Filed: July 24, 1998
    Date of Patent: December 4, 2001
    Assignee: Bristol-Myers Squibb Pharma Company
    Inventors: Jeffrey A. Miller, Elizabeth C. Arner, Robert A. Copeland, Gary L. Davis, Ruiqin Liu, Michael Pratta, Micky D. Tortorella
  • Patent number: 6326368
    Abstract: The present invention provides novel compounds, and pharmaceutical compositions thereof, and methods of using same in the treatment of affective disorders, anxiety, depression, post-traumatic stress disorders, eating disorders, supranuclear palsey, irritable bowl syndrome, immune supression, Alzheimer's disease, gastrointestinal diseases, anorexia nervosa, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorders, or fertility problems. The novel compounds provided by this invention are those of formula: wherein R1, R3, R5, Q, Z, Y, V, X and X′ are as defined herein.
    Type: Grant
    Filed: March 13, 1997
    Date of Patent: December 4, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Robert John Chorvat, Parthasarathi Rajagopalan
  • Patent number: 6313124
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I or II: and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
    Type: Grant
    Filed: January 28, 1998
    Date of Patent: November 6, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Liqi He, Paul Gilligan, Robert Chorvat, Argyrios Georgios Arvanitis
  • Patent number: 6294671
    Abstract: The present invention describes novel isoxazolo[1,5-a]pyrimidines of formula: wherein R is an aromatic or heteroaromatic ring, or pharmaceutically acceptable salt form thereof, which are useful as CRF antagonists.
    Type: Grant
    Filed: August 20, 1999
    Date of Patent: September 25, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventor: William Eric Frietze
  • Patent number: 6271380
    Abstract: Corticotropin releasing factor (CRF) antagonists of formula I: and their use in treating anxiety, depression, and other psychiatric, neurological disorders as well as treatment of immunological, cardiovascular or heart-related diseases and colonic hypersensitivity associated with psychopathological disturbance and stress.
    Type: Grant
    Filed: December 28, 1999
    Date of Patent: August 7, 2001
    Assignee: DuPont Pharmaceuticals Company
    Inventors: Paul Joseph Gilligan, Rajagopal Bakthavatchalam